Cite
HARVARD Citation
Caimi, P. et al. (n.d.). ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3Kδ INHIBITOR, FOR THE TREATMENT OF PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B‐CELL MALIGNANCIES (CITADEL‐101). Hematological oncology. p. 268. [Online].